Q32 Bio, Inc. (QTTB)
8.72
-0.10
(-1.13%)
USD |
NASDAQ |
Nov 13, 16:00
8.72
0.00 (0.00%)
After-Hours: 19:59
Q32 Bio Enterprise Value : -20.82M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | -20.82M |
| November 11, 2026 | -9.458M |
| November 10, 2026 | -5.572M |
| November 09, 2026 | -5.273M |
| November 06, 2026 | -7.963M |
| November 05, 2026 | -19.92M |
| November 04, 2026 | -16.33M |
| November 03, 2026 | -22.61M |
| November 02, 2026 | -24.10M |
| October 30, 2026 | -18.13M |
| October 29, 2026 | -19.32M |
| October 28, 2026 | -13.64M |
| October 27, 2026 | -24.10M |
| October 26, 2026 | -31.88M |
| October 23, 2026 | -25.90M |
| October 22, 2026 | -21.41M |
| October 21, 2026 | -25.30M |
| October 20, 2026 | -26.80M |
| October 19, 2026 | -51.61M |
| October 16, 2026 | -59.68M |
| October 15, 2026 | -52.20M |
| October 14, 2026 | -45.03M |
| October 13, 2026 | -43.53M |
| October 12, 2026 | -23.21M |
| October 09, 2026 | -35.16M |
| Date | Value |
|---|---|
| October 08, 2026 | -42.64M |
| October 07, 2026 | -45.63M |
| October 06, 2026 | -42.04M |
| October 05, 2026 | -34.27M |
| October 02, 2026 | -38.45M |
| October 01, 2026 | -37.86M |
| September 30, 2026 | -37.26M |
| September 29, 2026 | 125.24M |
| September 28, 2026 | 118.11M |
| September 25, 2026 | 107.20M |
| September 24, 2026 | 117.88M |
| September 23, 2026 | 125.95M |
| September 22, 2026 | 149.92M |
| September 21, 2026 | 147.55M |
| September 18, 2026 | 149.21M |
| September 17, 2026 | 156.81M |
| September 16, 2026 | 159.65M |
| September 15, 2026 | 164.16M |
| September 14, 2026 | 157.99M |
| September 11, 2026 | 162.50M |
| September 10, 2026 | 153.48M |
| September 09, 2026 | 163.45M |
| September 08, 2026 | 176.51M |
| September 04, 2026 | 183.63M |
| September 03, 2026 | 202.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.236B |
| Beam Therapeutics, Inc. | 1.686B |
| Prime Medicine, Inc. | 720.48M |
| Korsana Biosciences, Inc. | 994.55M |
| Prelude Therapeutics, Inc. | 146.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.922M |
| Total Expenses (Quarterly) | 8.922M |
| EPS Diluted (Quarterly) | -0.2622 |
| Earnings Yield | 38.33% |
| Operating Earnings Yield | 10.40% |
| Normalized Earnings Yield | 38.39 |